We observed that the high expression of SEC23A is positively associated with poor outcomes in OS, DSS, and PFI in BLCA, ACC, CESC, KIRP, and UVM patients (Figure 1A; Supplementary Table 1). Here, SEC23A is linked to adrenal cortex carcinoma.